Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Terbinafine in axial spondyloarthropathy
NCT05119712Phase 1Withdrawn
- Sponsor
- Oregon Health & Science University
- Start
- Mar 2021
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Terbinafine in axial spondyloarthritis (axSpA) (2 arms), sponsored by Oregon Health & Science University. Primary endpoint: Bath Ankylosing Spondylitis Disease Activity Index at 16 weeks. Planned start Mar 2021; status: withdrawn.
02
Drugs
Terbinafine
03
Conditions
axial spondyloarthritis (axSpA)
Beyond the preview
Go deeper on NCT05119712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05119712.